Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047281 · ClinicalTrials.gov registry record · Phase 2
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00047281: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT00047281 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047281, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and cyclophosphamide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and celecoxib with etoposide and cyclophosphamide in treating patients who have relapsed or refractory malignant glioma.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG thalidomide
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-03 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
What the finished NCT00047281 record still lists
NCT00047281 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00047281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00047281 about?
NCT00047281 is a clinical study titled "Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma". RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and cyclophosphamide may kill m...
What is the current status of trial NCT00047281?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-03. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00047281?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), thalidomide (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00047281?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia